Market Place
Sourcing Support
CCSB obtained US patent for Tofacitinib Citrate
11 Jan 2024 //
PRESS RELEASE
CCSB obtained US patent for Etelcalcetide
17 Jan 2023 //
PRESS RELEASE
CCSB accomplished Trandolapril audit.
12 Jan 2023 //
PRESS RELEASE
CCSB accomplished Methocarbamol remote audit.
20 Dec 2022 //
PRESS RELEASE
CCSB accomplished an inspection of The Food and Drug Administration (USFDA).
18 Nov 2022 //
PRESS RELEASE
CCSB accomplished Rapamycin remote audit
21 Oct 2022 //
PRESS RELEASE
CCSB accomplished Tacrolimus remote audit.
21 Sep 2022 //
PRESS RELEASE
CCSB accomplished EVE and Rapamycin remote audit.
16 Sep 2022 //
PRESS RELEASE
CCSB accomplished Sugammadex Sodiumaudit.
04 Aug 2022 //
PRESS RELEASE
Obtained Outstanding Company of the year, 2022 Taiwan BIO awards
28 Jul 2022 //
PRESS RELEASE
CCSB accomplished an inspection of Taiwan Food and Drug Administration (TFDA).
13 May 2022 //
PRESS RELEASE
CCSB accomplished Caspofungin and Trandolapril remote audit.
10 May 2022 //
PRESS RELEASE
CCSB accomplished Methocarbamol audit.
22 Apr 2022 //
PRESS RELEASE
CCSB accomplished Tacrolimus remote audit.
04 Mar 2022 //
PRESS RELEASE
CCSB accomplished Mycophenolate Mofetil remote audit.
25 Feb 2022 //
PRESS RELEASE
CCSB accomplished Methocarbamol remote audit.
21 Feb 2022 //
PRESS RELEASE
CCSB accomplished Caspofungin remote audit.
26 Jan 2022 //
PRESS RELEASE
CCSB obtained Taiwan patent for Etelcalcetide
24 Jan 2022 //
PRESS RELEASE
CCSB obtained Taiwan patent for Ethyl Icosapentate
24 Jan 2022 //
PRESS RELEASE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.